J. Safra Sarasin has announced today that it has acquired 100% of the shares of MIV Asset Management AG, Zurich (“MIV”). The group says that this acquisition highlights J. Safra Sarasin’s commitment to growth in Asset Management with its thematic equity investing capabilities.
MIV is renowned for its expertise in medical technology (“Medtech”) investments and its flagship MIV Global Medtech Fund. The firm is well known for its innovative approach and deep sector knowledge, making it a valuable addition to Bank J. Safra Sarasin’s portfolio of thematic equity strategies available to both private and institutional investors.
The Medtech sector is set to grow, driven by an aging global population, technological innovation, the rise of chronical diseases and the increasing healthcare access in emerging markets. Some of the most exciting opportunities, such as AI-driven applications, make it a compelling long-term investment case for investors.
MIV will maintain its existing investment strategy and organisational structure to ensure solid performance and uninterrupted service for clients.
Oliver Cartade, head of asset management & institutional clients division at Bank J. Safra Sarasin, commented:
“We are thrilled to welcome MIV Asset Management into the J. Safra Sarasin Group. This acquisition aligns perfectly with our strategic vision to strengthen our thematic equity offerings and underscores our commitment to providing clients with unparalleled investment opportunities. MIV’s exceptional team and proven track record will be instrumental in driving our growth and innovation in the thematic investing space.”
Christoph Gubler, senior portfolio manager and CEO of MIV Asset Management, said:
“We are excited to become part of the J. Safra Sarasin Group to ensure the long-term success of our investment strategy in the best interest of investors. We look forward to continuing our success story as part of the J. Safra Sarasin Group.”
Financial terms of the transaction are not disclosed.
